# Zepbound (tirzepatide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tirzepatide

> The FDA approved Zepbound (tirzepatide), sponsored by ELI LILLY & Co (LLY), on November 8, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Zepbound (tirzepatide) |
| Codes | LY3298176 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Obesity](https://sec-api.dev/indications/obesity), [Metabolic Dysfunction-Associated Steatotic Liver Disease](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatotic-liver-disease), Overweight, [Type 2 Diabetes Mellitus](https://sec-api.dev/indications/type-2-diabetes-mellitus), [Type 2 Diabetes](https://sec-api.dev/indications/type-2-diabetes), [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease), [Type 1 Diabetes](https://sec-api.dev/indications/type-1-diabetes) |
| Modality | peptide |
| FDA designations | priority review |

## Timeline

### May 13, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Mounjaro | tirzepatide | 5/13/2022 | To improve blood sugar control in diabetes, in addition to diet and exercise Press Release (FDA Archive)Drug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA215866 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20220513, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product MOUNJARO (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22

### November 8, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217806 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20231108, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22

### October 18, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217806 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20241018, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22

### December 20, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217806 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-02-13, last confirmed 2025-02-13.
- SEC Form 10-Q (accession 0001654954-25-001431): "the results of clinical trials with our late-stage products, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024 with topline results expected in the first quarter of calendar year 2025" https://www.sec.gov/Archives/edgar/data/911216/000165495425001431/ptn_10q.htm
- SEC Form 10-Q (accession 0001654954-25-001431): "Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results expected in the first quarter of calendar year 2025." https://www.sec.gov/Archives/edgar/data/911216/000165495425001431/ptn_10q.htm

### June 12, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." https://clinicaltrials.gov/study/NCT04255433

### 2H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-002826): "A Phase 2 study of trevogrumab and semaglutide with and without garetosmab is now fully enrolled and a Phase 2 study testing combinations of tirzepatide and mibavademab is ongoing, with initial data expected from both in the second half of 2025." https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm

### December 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06373146 (A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06373146

### December 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215866 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20251219, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product MOUNJARO (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22

### January 8, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Type 2 Diabetes; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06037252 (A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06037252

### January 16, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06643728 (A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06643728

### January 20, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06047548 (A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-20 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06047548

### June 2, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06075667 (A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06075667

### July 1, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06603571 (A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06603571

### July 6, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Overweight; Obesity; Chronic Kidney Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05536804 (A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05536804

### July 8, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." https://clinicaltrials.gov/study/NCT04255433?tab=results

### August 26, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217806 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20260826, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product ZEPBOUND (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217806%22
- openFDA Drugs@FDA: "NDA215866 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product MOUNJARO (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22
- openFDA Drugs@FDA: "NDA215866 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product MOUNJARO (TIRZEPATIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06662383 (A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06662383

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06662383 (A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06662383

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 1 Diabetes; Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06914895 (A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06914895

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 1 Diabetes; Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06914895 (A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06914895

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 1 Diabetes; Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06962280 (A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06962280

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 1 Diabetes; Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06962280 (A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06962280

### Q1 2027: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-02-11, last confirmed 2026-02-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-045527): "The Phase 2b PLATEAU clinical study is expected to begin in the first quarter of calendar 2026 and an interim analysis is planned for the first quarter of calendar 2027." https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771dex991.htm

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06143956 (A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06143956

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06143956 (A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06143956

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05556512 (A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05556512

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity; Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05556512 (A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT05556512

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity; Weight Gain.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06439277 (A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06439277

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity; Weight Gain.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06439277 (A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06439277

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ulcerative Colitis; Obesity or Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06937086 (Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06937086

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ulcerative Colitis; Obesity or Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06937086 (Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06937086

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease; Obesity or Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06937099 (Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06937099

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease; Obesity or Overweight.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06937099 (Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06937099

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07881432 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07881432

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07881432 (A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07881432

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity; Overweight; Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07881458 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07881458

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity; Overweight; Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07881458 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07881458

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07817875 (Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07817875

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07817875 (Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07817875

### August 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07165028 (A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07165028

### Aug to Nov 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07165028 (A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07165028

## Same indication

- [ABBV-295](https://sec-api.dev/pdufa/abbv-295) (ABBV)
- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Aln-cideb](https://sec-api.dev/pdufa/aln-cideb) (REGN)
- [AZD6234](https://sec-api.dev/pdufa/azd6234) (AZN)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Berobenatide](https://sec-api.dev/pdufa/berobenatide) (PFE)
- [Biological/vaccine](https://sec-api.dev/pdufa/biological-vaccine) (VRTX)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Cagrilintide](https://sec-api.dev/pdufa/cagrilintide) (NVO)
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) (NVO)
- [Farxiga (dapagliflozin)](https://sec-api.dev/pdufa/dapagliflozin) (AZN)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Trulicity (dulaglutide)](https://sec-api.dev/pdufa/dulaglutide) (LLY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Efinopegdutide](https://sec-api.dev/pdufa/efinopegdutide) (MRK)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Eloralintide](https://sec-api.dev/pdufa/eloralintide) (LLY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [High dose sab-142](https://sec-api.dev/pdufa/high-dose-sab-142) (SABS)
- [Icosema](https://sec-api.dev/pdufa/icosema) (NVO)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [KAI-7535](https://sec-api.dev/pdufa/kai-7535) (KLRA)
- [LY3457263](https://sec-api.dev/pdufa/ly3457263) (LLY)
- [LY3549492](https://sec-api.dev/pdufa/ly3549492) (LLY)
- [LY4086940](https://sec-api.dev/pdufa/ly4086940) (LLY)
- [Macupatide](https://sec-api.dev/pdufa/macupatide) (LLY)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Met097 injection](https://sec-api.dev/pdufa/met097) (PFE)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nimacimab](https://sec-api.dev/pdufa/nimacimab) (SKYE)
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111) (NVO)
- [NNC0662-0419](https://sec-api.dev/pdufa/nnc0662-0419) (NVO)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Oral semaglutide](https://sec-api.dev/pdufa/oral-semaglutide) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [Ormd-0801 8 mg](https://sec-api.dev/pdufa/ormd-0801) (ORMP)
- [PF-07976016](https://sec-api.dev/pdufa/pf-07976016) (PFE)
- [PF-08653944](https://sec-api.dev/pdufa/pf-08653944) (PFE)
- [PF-08653945](https://sec-api.dev/pdufa/pf-08653945) (PFE)
- [Renal autologous cell therapy (react/ rilparencel)](https://sec-api.dev/pdufa/renal-autologous-cell-therapy-react-rilparencel) (PROK)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [Ribupatide](https://sec-api.dev/pdufa/ribupatide) (KLRA)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [IMCIVREE® (setmelanotide)](https://sec-api.dev/pdufa/setmelanotide) (RYTM)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Taldefgrobep alfa](https://sec-api.dev/pdufa/taldefgrobep-alfa) (BHVN)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [NEREUSTM (tradipitant)](https://sec-api.dev/pdufa/tradipitant) (VNDA)
- [Trevogrumab-part a](https://sec-api.dev/pdufa/trevogrumab-part-a) (REGN)
- [UBT251](https://sec-api.dev/pdufa/ubt251) (NVO)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tirzepatide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zepbound (tirzepatide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tirzepatide

```bibtex
@misc{secapidev_pdufa_tirzepatide_20261116,
  title        = {Zepbound (tirzepatide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tirzepatide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tirzepatide_20261116","title":"Zepbound (tirzepatide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tirzepatide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
